Get the Stockscreener App
29.14
2.57%
0.73
Artivion Inc stock is traded at $29.14, with a volume of 837.87K.
It is up +2.57% in the last 24 hours and up +25.98% over the past month.
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
See More
Previous Close:
$28.41
Open:
$28.84
24h Volume:
837.87K
Relative Volume:
1.11
Market Cap:
$1.42B
Revenue:
$458.69M
Net Income/Loss:
$11.68M
P/E Ratio:
121.32
EPS:
0.2402
Net Cash Flow:
$14.58M
1W Performance:
+7.45%
1M Performance:
+25.98%
6M Performance:
-20.38%
1Y Performance:
-32.15%
1-Day Range:
$28.27
$29.24
1-Week Range:
$26.21
$29.34
52-Week Range:
$19.16
$48.25
Artivion Inc Stock (AORT) Company Profile
Name
Artivion Inc
Sector
Industry
Phone
(770) 419-3355
Address
1655 ROBERTS BOULEVARD N W, KENNESAW
Compare AORT vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AORT
Artivion Inc
|
29.14 | 1.40B | 458.69M | 11.68M | 14.58M | 0.2402 |
ABT
Abbott Laboratories
|
111.25 | 191.92B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
339.21 | 133.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
91.27 | 116.18B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
51.83 | 74.52B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
91.60 | 53.63B | 6.30B | 1.07B | 1.09B | 1.8406 |
Artivion Inc Stock (AORT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Aug-13-25 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-17-25 | Initiated | Canaccord Genuity | Buy |
| Oct-23-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-27-22 | Reiterated | Lake Street | Buy |
| Aug-08-22 | Initiated | Lake Street | Buy |
| Mar-03-22 | Initiated | Stifel | Buy |
View All
Artivion Inc Stock (AORT) Latest News
ARTIVION, INC. SEC Filing (Aug 14, 2026) - Stock Titan
AORT (AORT) investor files to sell 616 shares after 44,001-share sale - Stock Titan
Artivion (AORT): Nomura entities report 6.5% beneficial stake in 13G/A - Stock Titan
Artivion (AORT) Q2 2026 Earnings Call Transcript - AOL.com
Artivion Inc (AORT) SVP and General Counsel Jean Holloway Sells 977 Shares - GuruFocus
Jean Holloway Sells 977 Shares of Artivion (NYSE:AORT) Stock - MarketBeat
Artivion at canaccord growth conference: pipeline drives growth plan By Investing.com - Investing.com Canada
Artivion at canaccord growth conference: pipeline drives growth plan - Investing.com
Artivion SVP Jean Holloway sells 977 shares for $27,834 - Investing.com
Artivion (AORT) Is Up 5.5% After FDA AMDS Approval And Reaffirmed 2026 Revenue GuidanceWhat's Changed - simplywall.st
Artivion, Inc. (AORT) Stock Price, News, Quote & History - ca.finance.yahoo.com
Artivion Inc (AORT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Can Artivion (NYSE:AORT) Gain Ground on the NYSE Composite? - Kalkine Media
Artivion (NYSE:AORT) Stock Price Up 8.2%What's Next? - MarketBeat
Artivion, Inc. (AORT) stock price, news, quote and history - Yahoo Finance UK
Artivion revenue up 11% to USD 125.8M in Q2 2026 - Medical Buyer
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Artivion (AORT) and Globus Medical (GMED) - The Globe and Mail
Artivion (AORT) Stock Can Revenue Growth Outrun Fresh Losses? - Sahm
Canaccord raises Artivion stock price target on acquisition, PMA approval By Investing.com - Investing.com Australia
Artivion Q2 Earnings Call Highlights - MarketBeat
Artivion Announces Q2 2026 Financial Results: Revenue Increase and Net Loss Amid Endospan Acquisition - Kalkine Media
ARTIVION, INC. 2026: Revenue $125.76M, EPS ($0.28) — 10-Q Summary - TradingView
Long-Term Growth Opportunities Remain for Artivion (AORT) Despite Challenges - Yahoo Finance
A Quick Look at Today's Ratings for Artivion(AORT.US), With a Forecast Between $38 to $45 - Moomoo
Artivion Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Canaccord raises Artivion stock price target on acquisition, PMA approval - Investing.com
Earnings call transcript: Artivion tops Q2 2026 revenue forecast as shares rise - Investing.com Australia
Artivion's Q2 Adjusted Earnings Decline, Revenue Increases - marketscreener.com
Artivion Inc (AORT) (Q2 2026) Earnings Call Highlights: PMA Appr - GuruFocus
Artivion, Inc. 2026 Q2ResultsEarnings Call Presentation (NYSE:AORT) 2026-08-07 - Seeking Alpha
Artivion (NYSE:AORT) Issues Earnings Results - MarketBeat
Is Artivion Inc (AORT) Undervalued Despite $125.8 Million Revenue in Q2? GF Score: 82/100 - GuruFocus
Artivion Q2 2026 slides: dual FDA wins fuel aortic growth plan - Investing.com
Artivion (AORT) Q2 Earnings Meet Estimates - Yahoo Finance
Earnings Flash (AORT) Artivion, Inc. Reports Q2 Revenue $125.8M, vs. FactSet Est of $120.0M - marketscreener.com
Earnings Flash (AORT) Artivion, Inc. Posts Q2 Adjusted EPS $0.13 per Share, vs. FactSet Est of $0.10 - marketscreener.com
Earnings Flash (AORT) Artivion, Inc. Posts Q2 Adjusted EPS $0.13 per Share, Vs. FactSet Est of $0.10 - Moomoo
ARTIVION ($AORT) Releases Q2 2026 Earnings - quiverquant.com
Artivion (NYSE:AORT) Delivers Strong Q2 CY2026 Numbers - Yahoo Finance
Artivion Reports Second Quarter 2026 Financial Results - marketscreener.com
Artivion earnings on deck: Can FDA approval revive growth? By Investing.com - Investing.com Canada
Artivion earnings on deck: Can FDA approval revive growth? - Investing.com
FMR LLC, Abigail Johnson report 4.0% Artivion Inc (AORT) ownership in 13G/A - Stock Titan
Artivion Q2 2026 slides: FDA wins fuel aortic arch expansion By Investing.com - Investing.com Canada
Artivion (AORT) To Report Earnings Tomorrow: Here Is What To Expect - Barchart.com
Is Artivion (AORT) Undervalued As Investors Reassess Its Growth And Capital Efficiency? - finance.yahoo.com
Artivion, Inc. (AORT) Stock Analysis: Exploring a 52.89% Potential Upside in the Medical Device Sector - directorstalkinterviews.com
Artivion, Inc. (AORT) Stock Forecasts - Yahoo Finance
Perceptive Advisors LLC Sells 85,000 Shares of Artivion, Inc. $AORT - MarketBeat
Artivion, Inc. Revenue Breakdown – HAM:CYL - TradingView
Artivion (AORT) Projected to Post Earnings on Thursday - MarketBeat
Artivion Inc Stock (AORT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
1.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):